All articles by  

  1. Trialbee collaborates with TriNetX for patient-centric trials

    Trialbee offers software to cut trial recruitment timelines and improve the patient engagement experience, while TriNetX works to optimise clinical…
    Read More…

    16 Oct
  2. Replimune enrols first patient in Phase II CSCC study

    The drug candidate will be investigated in combination with Libtayo (cemiplimab-rwlc) and developed by Regeneron and Sanofi to treat cutaneous…
    Read More…

    16 Oct
  3. Trial shows tranexamic acid could reduce head injury deaths

    TXA inhibits blood clot breakdown and prevents bleeding into the brain. The CRASH-3 trial showed that the drug led to…
    Read More…

    15 Oct
  4. MorphoSys and I-Mab to expand multiple myeloma trials to China

    The trials are being conducted in Taiwan to assess MorphoSys’s human monoclonal antibody, MOR202/TJ202, which acts against CD38 present on…
    Read More…

    15 Oct
  5. Signant Health offers eConsent support for oncology trial in UK

    The university’s National Institute for Health Research Bristol Biomedical Research Centre (NIHR Bristol BRC) will use Signant Health’s TrialConsent solution…
    Read More…

    15 Oct
  6. New trial announced to assess cannabidiol in Parkinson’s patients

    The trial will be conducted by King’s College London in alliance with charity Parkinson’s UK, which has committed £1.2m to…
    Read More…

    14 Oct
  7. Pfizer’s abrocitinib meets all endpoints in JADE MONO-1 study

    The 12-week study compared a 200mg and 100mg dose of abrocitinib with placebo in 387 patients aged 12 years and…
    Read More…

    14 Oct
  8. Florence raises funds to digitally link sites and sponsors

    The financing round was led by Fulcrum Equity Partners. Atrium Health and Bee Partners also joined the funding round. Over…
    Read More…

    14 Oct
  9. Seattle Genetics starts combination therapy trial in breast cancer

    Tucatinib is an investigational, oral, small-molecule tyrosine kinase inhibitor with high selectivity for HER2 that is overexpressed in various cancer…
    Read More…

    11 Oct
  10. Alder commences ALD1910 dosing in Phase I migraine trial

    ALD1910 inhibits pituitary adenylate cyclase-activating polypeptide (PACAP), which is a key signalling molecule in the pathophysiology of migraine. PACAP and…
    Read More…

    11 Oct
Close
Close
Close

Go Top